-
1.发明申请EFFICIENT AND STABLE (IN VIVO) GENE TRANSFER TO CARDIOMYOCYTES USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS 审中-公开使用重组腺病毒相关病毒载体转运到心脏细胞的有效和稳定的（i VIVO）
公开(公告)号：WO0038518A9
公开(公告)日：2002-04-11
申请号：PCT/US9931093
申请日：1999-12-28
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , SVENSSON ERIC
IPC: C12N15/09 , A61K31/711 , A61K35/76 , A61K38/00 , A61K38/04 , A61K48/00 , A61P9/04 , A61P9/06 , A61P9/08 , A61P9/10 , C12N15/864 , A01N43/04 , A61K31/70 , C12N15/00 , C12N15/63
CPC classification number: C12N15/86 , A61K48/00 , C12N2750/14143
Abstract: This invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes DOLLAR I(in vivo) by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.
Abstract translation: 本发明涉及使用重组腺相关病毒（rAAV）载体通过将rAAV注入冠状动脉或冠状窦来转导心肌细胞DOLLAR I（体内）。 rAAV感染与可检测的心肌炎症或心肌细胞坏死无关。 因此，rAAV是用于在心肌中稳定表达治疗基因的有用载体，可用于递送用于诱导血管发生，抑制血管生成，刺激细胞增殖，抑制细胞增殖和/或治疗或改善其它心血管病症的基因。
-
公开(公告)号：JP2003102474A
公开(公告)日：2003-04-08
申请号：JP2002274149
申请日：2002-09-19
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , BARR ELIAV
IPC: C12N15/09 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/22 , A61K45/00 , A61K48/00 , A61P9/10 , C07K14/47 , C12N5/10 , C12N15/12 , C12N15/861 , C12P21/00 , C12R1/91
Abstract: PROBLEM TO BE SOLVED: To provide a specific gene expression to cardiac muscle and to coronary vascular smooth muscle. SOLUTION: This method is used for expression of a gene product in a cardiac muscle cell and comprises (a) a step for infusing an adenovirus vector construct comprising a coding sequence that encodes the gene product into the blood flow of a coronary artery or a coronary sinus perfusing the cardiac muscle cell wherein the vector drives expression of the gene product in the muscle cell and (b) a step for obtaining expression of the gene product in the cardiac muscle cell.
-
3.发明公开EFFICIENT AND STABLE $I(IN VIVO) GENE TRANSFER TO CARDIOMYOCYTES USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS 审中-公开高效，稳定-I（体内）的基因转移CARDIOMYCETEN使用重组腺相关病毒载体
公开(公告)号：EP1139751A4
公开(公告)日：2003-03-19
申请号：EP99967703
申请日：1999-12-28
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , SVENSSON ERIC
IPC: C12N15/09 , A61K31/711 , A61K35/76 , A61K38/00 , A61K38/04 , A61K48/00 , A61P9/04 , A61P9/06 , A61P9/08 , A61P9/10 , C12N15/864 , A01N43/04 , A61K31/70 , C12N15/00 , C12N15/63
CPC classification number: C12N15/86 , A61K48/00 , C12N2750/14143
-
公开(公告)号：DE69333886T2
公开(公告)日：2006-07-27
申请号：DE69333886
申请日：1993-11-16
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , BARR ELIAV
IPC: C12N15/09 , C12N15/86 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/22 , A61K45/00 , A61K48/00 , A61P9/10 , C07K14/47 , C12N5/10 , C12N15/12 , C12N15/63 , C12N15/861 , C12P21/00 , C12R1/91
Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus vector construct intravascularly.
-
公开(公告)号：AT307212T
公开(公告)日：2005-11-15
申请号：AT99109240
申请日：1993-11-16
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , BARR ELIAV
IPC: C12N15/09 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/22 , A61K45/00 , A61K48/00 , A61P9/10 , C07K14/47 , C12N5/10 , C12N15/12 , C12N15/861 , C12P21/00 , C12R1/91 , C12N15/86 , C12N15/63
Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus vector construct intravascularly.
-
Patent Agency Ranking
公开(公告)号：AU763049B2
公开(公告)日：2003-07-10
申请号：AU2394200
申请日：1999-12-28
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , SVENSSON ERIC
-
公开(公告)号：DE69333886D1
公开(公告)日：2006-03-02
申请号：DE69333886
申请日：1993-11-16
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , BARR ELIAV
IPC: C12N15/09 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/22 , A61K45/00 , A61K48/00 , A61P9/10 , C07K14/47 , C12N5/10 , C12N15/12 , C12N15/63 , C12N15/86 , C12N15/861 , C12P21/00 , C12R1/91
Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus vector construct intravascularly.
-
公开(公告)号：CA2356551A1
公开(公告)日：2000-07-06
申请号：CA2356551
申请日：1999-12-28
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , SVENSSON ERIC
IPC: C12N15/09 , A61K31/711 , A61K35/76 , A61K38/00 , A61K38/04 , A61K48/00 , A61P9/04 , A61P9/06 , A61P9/08 , A61P9/10 , C12N15/864 , A01N43/04 , A61K31/70 , C12N15/00 , C12N15/63
Abstract: This invention relates to the use of recombinant adeno-associated virus (rAA V) vectors to transduce cardiomyocytes $I(in vivo) by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a usef ul vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.
-
公开(公告)号：AU4502096A
公开(公告)日：1996-06-06
申请号：AU4502096
申请日：1995-11-13
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , BARR ELIAV
-
公开(公告)号：CA2149771A1
公开(公告)日：1994-05-26
申请号：CA2149771
申请日：1993-11-16
Applicant: ARCH DEV CORP
Inventor： LEIDEN JEFFREY M , BARR ELIAV
IPC: C12N15/09 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/22 , A61K45/00 , A61K48/00 , A61P9/10 , C07K14/47 , C12N5/10 , C12N15/12 , C12N15/861 , C12P21/00 , C12R1/91 , C12N15/86
Abstract: 2149771 9411506 PCTABS00032 The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus vector construct intravascularly.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.022 seconds)
